Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitors and the Treatment of Hypercholesterolemia

Proprotein Convertase Subtilisin/kexin Type 9 (PCSK9) Inhibitors and the Treatment of Hypercholesterolemia is organized by ProCE, LLC.,Release Date: January 31, 2022,Expiration Date: January 31, 2025,,Description :,This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice.This activity lays the foundation for understanding the disease state, the various clinical aspects of the drug class, and the pipeline involving this class of specialty pharmacy medications.,,Learning Objectives:,Upon completion of this activity, participants will be able to:,• Explain the pathophysiology of hypercholesterolemia.,• Define current therapy guidelines for hypercholesterolemia.,• Review the Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors.,• Discuss the PCSK9 pipeline.,• Review the role of the Specialty Clinician in caring for patients receiving PCSK9